Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.

doi:10.1158/2767-9764.CRC-24-0338

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.

Cancer research communications - 1 Sept 2024

Ek Torben, Ibrahim Raghda R, Vogt Hartmut, Georgantzi Kleopatra, Träger Catarina, Gaarder Jennie, Djos Anna, Rahmqvist Ida, Mellström Elisabeth, Pujol-Calderón Fani, Vannas Christoffer, Hansson Lina, Fagman Henrik, Treis Diana, Fransson Susanne, Österlund Tobias, Chuang Tzu-Po, Verhoeven Bronte Manouk, Ståhlberg Anders, Palmer Ruth H, Hallberg Bengt, Martinsson Tommy, Kogner Per, Dalin Martin

Abstract excerpt

Patients with anaplastic lymphoma kinase (ALK)-driven neuroblastoma may respond to tyrosine kinase inhibitors, but resistance to treatment occurs and methods currently used for detection of residual disease have limited sensitivity. Here, we present a national unselected cohort of five patients with relapsed or refractory ALK-driven neuroblastoma treated with lorlatinib as monotherapy and test the potential of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anaplastic Lymphoma Kinase

Share to Circulating Tumor DNA

Share to Lactams

Share to Lactams, Macrocyclic

Share to Neoplasm Recurrence, Local

Share to Neuroblastoma

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 39177282
DOI: 10.1158/2767-9764.CRC-24-0338
PMCID: PMC11440348

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.PMID 39177282Read ↗

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.Semantic proximity Read ↗

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.Semantic proximity Read ↗

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCSemantic proximity Read ↗

Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.Semantic proximity Read ↗

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNASemantic proximity Read ↗

Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.Semantic proximity Read ↗

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.Semantic proximity Read ↗

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.Semantic proximity Read ↗

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysisSemantic proximity Read ↗

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.Semantic proximity Read ↗

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in NeuroblastomaSemantic proximity Read ↗

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.